More Stories

Informist, Friday, Mar. 13, 2026

 

MUMBAI – Shares of pharmaceutical companies are expected to move in a range next week. Technical analysts believe pharma stocks are a defensive bet in the current turbulent trading environment, as other sectors have corrected sharply due to a spike in crude oil prices. The imminent launch of a generic of blockbuster weight-loss drug semaglutide in India, and tailwinds from the rupee's depreciation are adding to the sector's merits, analysts said.

 

"We suggest a buy-on-dips trading approach in the pharmaceutical space," said Vipin Kumaar, technical and derivatives analyst at Globe Capital Markets. The analyst added that the Nifty Pharma index has been range-bound for a while. The lows and highs of the index will likely be contained within the 22200-23600 range, the analyst said. This week, the index ended 0.6% lower at 22832.20 points compared to a fall of over 5% in the benchmark Nifty 50.

 

"One segment that is weathering the storm is pharmaceuticals," V.K. Vijayakumar, chief investment strategist at Geojit Investments Ltd., said in a note. "This sector is not impacted by external headwinds." Rupee depreciation is a positive for the sector since it is heavily involved in exports, he added. "It appears that portfolio churns are happening in favour of pharmaceuticals."

 

Analysts are optimistic about the prospects of bigger players entering the generic glucagon-like peptide-1 market. These drugs will provide strong growth opportunities for these companies and will likely start reflecting in the financial performance by the start of the next financial year, analysts said. Sector majors like Dr. Reddy's Laboratories, Cipla, and Sun Pharmaceutical Industries have already announced plans to launch the generic GLP-1 drug when the patent for semaglutide expires on Mar. 20.

 

Analysts said that though pricing pressure may hurt overall sales, the weight-loss market lies largely untapped, providing sizeable revenue opportunity for companies. Around 40–50 generic brands of semaglutide are set to enter the market later this month, several analysts said. Prices of the generic drug may start from one-third of the current market price of their branded peers Wegovy and Ozempic, a report by The Indian Express said.

 

TOP HEADLINES

* Aurobindo Pharma to appeal against INR 1.55-bln GST demand
* Caplin Point arm gets US FDA approval for potassium phosphates vials
* Zydus Life gets US FDA final nod for Cevimeline Hydrochloride capsules
* Biocon arm gets US FDA nod for diabetes drug, Liraglutide injectable
* Zydus Life to launch AI-powered continuous glucose monitoring devices
* Aarti Ind bags $150-mln multi-yr supply deal with global agrochemical major
* US FDA issues 5 observations to Aurobindo Pharma arm unit in Andhra Pradesh
* Frame compensation norms for adverse events post COVID vaccines - SC to govt
* Cipla's US arm recalls unexpired batches of lanreotide injection
* Alembic Pharma incorporates subsidiary in Thailand to grow business
* Delhi HC bench allows Dr Reddy's to export semaglutide to some nations
* Lupin gets two US FDA observations for Gujarat manufacturing unit
* OneSource Specialty gets bourses' in-principle ok to buy Steriscience units
* Dr Reddy's says US justice dept has closed corruption inquiry against co

 

Following are the resistance and support levels for key pharmaceutical stocks for next week as per calculations based on their prices on the National Stock Exchange:

 

Company	Price	Week-on-Week Change in %	Resistance	Support
Abbott India	26,960.00	(-)1.30	27,806.70	25,866.70
Alkem Laboratories	5,355.50	(-)3.20	5,523.50	5,251.50
Aurobindo Pharma	1,296.50	5.20	1,330.50	1,271.10
Biocon	383.55	(-)1.80	404.40	372.20
Cipla	1,314.70	(-)0.50	1,340.90	1,287.90
Divi's Laboratories	6,071.00	(-)4.10	6,421.70	5,879.70
Dr Reddy's Laboratories	1,292.30	(-)0.90	1,336.70	1,258.70
Gland Pharma	1,626.60	(-)2.50	1,683.60	1,573.20
GlaxoSmithKline Pharmaceuticals	2,424.30	(-)3.70	2,543.00	2,338.40
Glenmark Pharmaceuticals	2,170.70	2.20	2,302.40	2,097.80
Granules India	562.20	(-)2.60	597.40	537.30
Ipca Laboratories	1,561.30	4.50	1,597.80	1,519.20
Laurus Labs	1,003.40	(-)2.20	1,081.30	941.90
Lupin	2,314.90	(-)1.20	2,389.40	2,260.00
Natco Pharma	955.85	(-)6.30	1,044.60	906.70
Pfizer	4,623.00	(-)4.70	4,734.70	4,534.70
Sanofi India	3,501.30	(-)7.50	3,640.60	3,425.60
Sun Pharmaceutical Industries	1,801.60	0.10	1,846.90	1,774.30
Torrent Pharmaceuticals	4,390.00	1.70	4,533.90	4,288.10
Zydus Lifesciences	905.90	(-)0.80	933.80	887.60
Index	Levels
Nifty Pharma	22832.20	(-)0.60	23513.10	22440.20
Nifty 50	23151.10	(-)5.30	23632.20	22871.40
S&P BSE Sensex	74563.92	(-)5.50	75986.50	73743.30

 

End

 

Reported by Eshitva Prakash

Edited by Ashish Shirke

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.